Limited point of care diagnostic testing for AHI and delayed recognition of infection continue to lead to under-recognition and under-reporting of neurologic manifestations of AHI. AHI should be on the differential for a broad range of neurological conditions, from Bell's palsy, peripheral neuropathy, and aseptic meningitis, to more rare manifestations such as ADEM, AIDP, meningo-radiculitis, transverse myelitis, and brachial neuritis. Treatment for these conditions involves early initiation of antiretroviral therapy (ART) and then standard presentation-specific treatments. Current HIV cure strategies under investigation include bone marrow transplant, viral reservoir re-activation and eradication, and genome and epigenetic viral targeting. However, CNS penetration by HIV-1 occurs early on in the disease course with the establishment of the CNS viral reservoir and is an important limiting factor for these therapies.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- sars cov
- bone marrow
- blood brain barrier
- mesenchymal stem cells
- liver failure
- dna methylation
- genome wide
- risk factors
- south africa
- helicobacter pylori infection
- drug induced
- water quality
- respiratory failure
- drug delivery
- hepatitis c virus
- case report
- combination therapy
- emergency department
- acute respiratory distress syndrome
- hepatitis b virus
- aortic dissection
- extracorporeal membrane oxygenation
- cerebrospinal fluid
- electronic health record